Failure of accelerated neutron therapy to control high grade astrocytomas

Saroja, K.R.; Mansell, Joanne; Hendrickson, Frank R.; Cohen, Lionel; Lennox, A.J.

doi:10.1016/0360-3016(89)90539-7

Cited by 24 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite recent advances in the understanding of the pathophysiology of this neoplasm, little progress has been achieved in treatment (Laws and Thapar, 1993;Damek and Hochberg, 1997;Prados and Levin, 2000). Patients with glioblastoma have poor prognosis, even when submitted to surgery, radiation and chemotherapy combined (Damek and Hochberg, 1997;Prados and Levin, 2000;Saroja et al, 1989;Chauvenic et al, 1996). The development of successful therapeutical approaches for malignant gliomas depends on further investigation into their biology (Kruse et al, 1998).…”

mentioning

confidence: 98%

Immunophenotypic and Ultrastructural Validation of a New Human Glioblastoma Cell Line

et al. 2005

View full text Add to dashboard Cite

1. A human glioma cell line, NG97, was established by Grippo et al. in 2001 from tissue obtained from a grade III astrocytoma (WHO, 2000). In this first study, the cell line grew as two morphologically distinct subpopulations: dendritic/spindle cells and small round cells. The injection of NG97 cells into nude mice induced an aggressive tumor characterized by: severe cytological atypia, vascular proliferation and pseudopalisading necrosis (glioblastoma multiforme features). 2. The purpose of the present study was to characterize the immunophenotype and ultrastructural aspects of this cell line, using the parental tumor, cultured cells and the xenotransplant, in order to assess its glial nature and possible divergent differentiation. 3. NG97 cells and xenotransplant expressed the main neuroglial markers (GFAP, S-100 protein, NSE and Leu-7) and showed no aberrant expression of other histogenetic markers. GFAP was similarly expressed in the parental tumor and in the cells in culture, but decreased in the xenotransplant. NSE expression was reduced in NG97 cells, but substantially recovered in the xenotransplant. This variability in expression of GFAP and NSE was interpreted as either a phenomenon of dedifferentiation or to microenvironmental selection of specific subclones. S-100 was equally expressed in the three contexts. The xenotransplant's ultrastructural features were those of a highly undifferentiated tumor. No significant immunophenotypic or ultrastructural differences between the two morphologically distinct populations were found. 4. Thus, our data demonstrate that NG97 cells constitute a pure glial-committed cell line, which may prove useful as a malignant glioma model in studies addressing pathophysiological, diagnostic and therapeutic issues.

show abstract

mentioning

confidence: 98%

Immunophenotypic and Ultrastructural Validation of a New Human Glioblastoma Cell Line

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The clinical trials on fast neutron therapy for brain tumors did not show any advantage over photon therapy [36,37] considering the life quality and survival time of the patients. Autopsy studies revealed considerably greater tumor destruction in the neutron-treated patients compared with those receiving photon treatments, but survival was limited by the onset of fatal postirradiation gliosis.…”

Section: Fast Neutron Therapymentioning

confidence: 99%

Design of a boron neutron capture enhanced fast neutron therapy assembly

Wang

2006

View full text Add to dashboard Cite

“…24 The most nonspecific class of BNCT agents is represented by the "first generation" bo ron carriers, used when the mechanisms of cell replica tion and receptor mediated recognition were not yet fully understood to have a significant impact on tailor made drug design. Other types of boron carriers include nucleic acid precursors or other essential cell metabolite precur sors (3,4,5,9). 1).…”

Section: Major Nct Drug Prototypesmentioning

confidence: 99%